Skip to main content
Premium Trial:

Request an Annual Quote

Bio Ventures to Oversee Alnylam, GSK IP Pool for Neglected Disease Research

Premium

Alnylam Pharmaceuticals and GlaxoSmithKline have selected non-profit Bio Ventures for Global Health to oversee the an intellectual property pool that the companies formed last year to assist with the discovery and development of new treatments for neglected tropical diseases.

"By adopting a more accessible approach to intellectual property, the pool facilitates access to compounds and technologies and, most importantly, industrial know-how for organizations that want to conduct research on treatments for these neglected diseases," the companies said.

As the pool's administrator, Bio Ventures will organize disease-specific meetings to "identify the gaps in expertise and intellectual property that currently exist in product development for neglected diseases," they added. "Bio Ventures for Global Health will then help global health researchers work with industry to fill these gaps so that the resources generously made available by companies will be used to create medicines for neglected diseases faster and more efficiently."

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.